Managed Care Update: Improving Outcomes for Narcolepsy Web Activity

Release Date: March 21, 2019
Expiration Date: September 30, 2020
Estimated Time to Complete Activity: 1.0 hour
Compatible with all modern browsers and mobile devices

EXPERT FACULTY


	Jeffrey Dunn, PharmD, MBA Vice President, Clinical Strategy and Programs and Industry Relations Magellan Rx Management Click here for biography

	Phyllis Zee, MD, PhD Benjamin and Virginia Professor in Neurology Chief, Division of Sleep Medicine Director, Center for Circadian and Sleep Medicine Northwestern University Feinberg School of Medicine Click here for biography

	John Fox, MD, MHA Vice President, Associate Chief Medical Officer Medical Affairs Priority Health Click here for biography

TARGET AUDIENCE

Managed care pharmacy directors, clinical pharmacists, quality directors, medical directors
Pharmacy directors, specialty pharmacists, quality directors, care managers, registered nurses, and other managed care and payer organization professionals

STATEMENT OF NEED/PROGRAM OVERVIEW

Narcolepsy is a chronic, incurable, and potentially disabling neurologic disorder that is primarily characterized by excessive sleepiness (EDS) and signs of rapid eye movement (REM) sleep dissociation, such as cataplexy. The clinical, psychosocial, and socioeconomic consequences of poor sleep quality and EDS can be severe, with variable and potentially devastating manifestations that range from cardiovascular events and psychiatric comorbidities to poor occupational performance and motor vehicle accidents. The prevalence of narcolepsy with and without cataplexy (i.e., narcolepsy types 1 and 2, respectively) has been examined in a number of studies, with reports as high as 50 cases per 100,000 people. In conjunction with the considerable reduction in health-related quality of life (HRQL) and remarkable health care resource utilization among plan members with narcolepsy, the relative permeation of the condition among all ages and ethnicities of male and female plan members is noteworthy for managed care stakeholders. Furthermore, an epidemic of under-recognition and misdiagnosis of narcolepsy serves to exacerbate its disease burden from the payer perspective.

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be able to demonstrate improved ability to:

Outline the current diagnostic criteria for narcolepsy and identify associated procedures to facilitate timely claims/prior authorization approval and treatment
Describe the available validated scales and patient questionnaires for identifying narcolepsy symptoms and evaluate their respective benefits and disadvantages for standardized use among network providers
Evaluate current pharmacologic treatments for narcolepsy based on available efficacy, safety, and cost data
Incorporate value-driven assessment approaches for member drug benefit design and appropriate formulary positioning of narcolepsy therapies
Implement plan-wide initiatives to better coordinate care for narcolepsy among primary care physicians, sleep specialists, and ancillary providers

ACCREDITATION

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-19-609-H01-P)

Type of Activity: Application

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

*Name of Faculty or Presenter*	*Reported Financial Relationship*
Jeffrey Dunn, PharmD, MBA	Dr. Dunn has nothing to disclose
Phyllis Zee, MD, PhD	Consulting Fees (e.g., advisory boards) – Jazz Pharmaceuticals, Harmony, Eisai / Purdue, Philips Contracted Research – Philips, Harmony Ownership Interest (stocks, stock options or other ownership interest excluding diversified mutual funds) - Teva Dr. Zee’s spouse has reported ownership interest with Teva.
John Fox, MD, MHA	Dr. Fox has nothing to disclose

The PIM planners and managers have nothing to disclose.
The Impact Education, LLC planners and managers have nothing to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the accreditation period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.